A diversified healthcare compounder temporarily discounted by litigation and post-deal noise—while CGM and oncology diagnostics reset Abbott’s growth runway.
Overview
Abbott Laboratories is a diversified global healthcare leader spanning Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals, designed to capture value across the patient lifecycle—from screening and prevention through chronic disease management and interventional treatment. In 2026, Abbott generates roughly $44–$50B in annual revenue with segment contribution led by Medical Devices (~45%), then Diagnostics (~20–25%), Nutrition (~18–20%), and Established Pharma (~12–15%). The portfolio’s growth centerpiece is FreeStyle Libre CGM, a mass-access biowearable platform that benefits from recurring sensor replacement economics and expanding indications. Strategically, Abbott is reshaping Diagnostics through the $23B acquisition of Exact Sciences (closed March 23, 2026), shifting from pandemic-era testing toward high-growth oncology screening and precision diagnostics (e.g., Cologuard, Oncotype DX). The company combines scale manufacturing, a global footprint across 160+ countries, and strong brand trust to win on “cost-and-access” and workflow simplification (Alinity’s unified lab platform). Near-term investor attention is split between durable base-business momentum and overhangs from NEC infant formula litigation and integration execution, leaving the stock priced at a discount to historical multiples.